Luspatercept for early anemia after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a medication called luspatercept can help raise red blood cells faster after a stem cell transplant for blood cancer. It aims to reduce severe anemia and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old and have had a donor stem cell transplant for a blood cancer.
- Your hemoglobin level (the part of blood that carries oxygen) was very low right after the transplant.
- You must be able to care for yourself reasonably well (ECOG score 0-2) and be expected to live at least a month.
- You must not have a severe uncontrolled infection, serious organ damage, or recent major heart or brain problems.
- You must be able to give consent (or have a family member do so) and not be in another transplant study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests a drug called luspatercept to see if it can help your body make blood cells faster after a stem cell transplant. It is for people with blood cancers and moderate to severe bone marrow scarring (myelofibrosis).
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
This study tests a drug called luspatercept for people with a mild form of aplastic anemia who still need frequent blood transfusions. Luspatercept may help your body make more red blood cells, reducing the need for transfusions and improving your energy.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.